# Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP

> **NCT04054882** · PHASE4 · COMPLETED · sponsor: **China National Biotec Group Company Limited** · enrollment: 702 (actual)

## Conditions studied

- Vaccination

## Interventions

- **BIOLOGICAL:** Sabin-IPV and DTaP
- **BIOLOGICAL:** Sabin-IPV
- **BIOLOGICAL:** DTaP

## Key facts

- **NCT ID:** NCT04054882
- **Lead sponsor:** China National Biotec Group Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-08-16
- **Primary completion:** 2020-03-30
- **Final completion:** 2021-09-09
- **Target enrollment:** 702 (ACTUAL)
- **Last updated:** 2022-07-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04054882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04054882, "Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04054882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*